Entod Pharmaceuticals on Tuesday announced that it has received final approval from the Drug Controller General of India (DCGI) for its PresVu eye drops.
During a press conference today in New Delhi, the company leadership announced that this approval follows an earlier recommendation by the Subject Expert Committee (SEC) of the Central Drugs Standard Control Organisation (CDSCO).
“PresVu is the first eye drop in India specifically developed to reduce dependency on reading glasses for individuals affected by presbyopia, a common age-related vision condition that typically impacts those over 40. Presvu has also been applied for a patent for this invention in terms of its formulation and the process. The proprietary formula not only gets rid of reding glasses but also helps the patient lubricate their eyes as a side benefit,” the company said in a statement.
According to the company’s press statement, these eye drops utilise advanced dynamic buffer technology to swiftly adapt to tear pH, ensuring consistent efficacy and safety for extended use, keeping in mind that such drops will be used for years at a stretch
According to a report, between 1.09 billion and 1.80 billion individuals globally are estimated to be affected by presbyopia. Its impact is both widespread and affects domestic productivity on a large scale.
Presbyopia occurs as a natural consequence of aging when the eye’s ability to focus diminishes, leading to difficulty in focusing on close objects.
This condition can significantly impact a person’s quality of life, affecting their ability to perform daily tasks and maintain their lifestyle. Many first notice presbyopia when they start holding reading materials at arm’s length to see them clearly. A basic eye exam can confirm the diagnosis.
“PresVu is the result of years of dedicated research and development. This DCGI approval is a major step forward in our mission to transform eye care in India. PresVu is more than just a product; it’s a solution that stands to improve the lives of millions by offering them greater visual independence. We take pride in our commitment to innovation and in providing healthcare solutions that are both accessible and affordable,” Nikkhil K Masurkar, CEO of ENTOD Pharmaceuticals, said during the press conference today.
ENTOD Pharmaceuticals has versatile offering in key areas of ENT, ophthalmology, pediatrics, and dermatology.
As PresVu moves toward commercial launch, ENTOD continues to drive innovation and support the ‘Make in India’ initiative, ensuring that advanced treatments are accessible to all, it added.
link